Clinical trial
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
NCT05592756 is registered in ClinicalTrials.gov with The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
- Lead sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 6, 2020
- Completion date
- March 31, 2022
- Enrollment
- 2,964 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.